Halozyme Therapeutics, Inc. (HALO)
Stock Price:
$30.83 USD
-0.27 (-0.87%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
After-hours: $31.30 +0.47 (1.51%) Oct 26, 6:27 PM
Key Info
| Market Cap |
4.22B |
| Revenue (ttm) |
180.47M |
| Net Income (ttm) |
-39.70M |
| Shares Out |
137.03M |
| EPS (ttm) |
-0.28 |
| PE Ratio |
n/a |
| Forward PE |
26.04 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$30.83 |
| Previous Close |
$31.10 |
| Change ($) |
-0.27 |
| Change (%) |
-0.87% |
| Day's Open |
30.73 |
| Day's Range |
30.26 - 31.34 |
| Day's Volume |
1,714,317 |
| 52-Week Range |
12.71 - 31.64 |
More Stats
| Market Cap |
4.22B |
| Enterprise Value |
4.23B |
| Earnings Date (est) |
Nov 2, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
137.03M |
| Float |
131.84M |
| EPS (basic) |
-0.26 |
| EPS (diluted) |
-0.28 |
| FCF / Share |
-0.44 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
14.63M |
| Short Ratio |
13.59 |
| Short % of Float |
11.10% |
| Beta |
1.62 |
| PE Ratio |
n/a |
| Forward PE |
26.04 |
| P/FCF Ratio |
n/a |
| PS Ratio |
23.41 |
| PB Ratio |
40.35 |
| Revenue |
180.47M |
| Operating Income |
-30.27M |
| Net Income |
-39.70M |
| Free Cash Flow |
-59.40M |
| Net Cash |
-4.13M |
| Net Cash / Share |
-0.03 |
| Gross Margin |
14.87% |
| Operating Margin |
-16.77% |
| Profit Margin |
-22.00% |
| FCF Margin |
-32.91% |
| ROA |
-0.25% |
| ROE |
-21.72% |
| ROIC |
-3.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (11)
| Buy |
9 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$32.73*
(6.16% upside)
Low
14.0
Current: $30.83
High
43.0
Target: 32.73
*Average 12-month price target from 11 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 196 | 152 | 317 | 147 | 135 | 75.33 | 54.80 | 42.33 | 56.09 | 13.62 |
| Revenue Growth | 29.06% | -52.04% | 115.84% | 8.61% | 79.28% | 37.47% | 29.47% | -24.54% | 311.67% | - |
| Gross Profit | 150 | 142 | 285 | 113 | 106 | 52.60 | 48.55 | 41.23 | 55.83 | 12.64 |
| Operating Income | -67.61 | -69.33 | 81.00 | -83.21 | -27.45 | -63.04 | -80.43 | -53.63 | -19.84 | -54.26 |
| Net Income | -72.24 | -80.33 | 62.97 | -103 | -32.23 | -68.38 | -83.48 | -53.55 | -19.77 | -53.24 |
| Shares Outstanding | 144 | 144 | 136 | 128 | 127 | 123 | 113 | 111 | 103 | 94.36 |
| Earnings Per Share | -0.50 | -0.56 | 0.45 | -0.81 | -0.25 | -0.56 | -0.74 | -0.48 | -0.19 | -0.56 |
| Operating Cash Flow | -85.42 | -49.50 | 134 | -50.38 | -37.08 | -47.52 | -49.34 | -64.28 | -34.30 | -45.39 |
| Capital Expenditures | -4.04 | -4.66 | -1.35 | -3.14 | -2.36 | -1.37 | -2.30 | -1.41 | -0.83 | -0.65 |
| Free Cash Flow | -89.46 | -54.16 | 133 | -53.52 | -39.44 | -48.89 | -51.64 | -65.69 | -35.13 | -46.03 |
| Cash & Equivalents | 422 | 355 | 470 | 205 | 109 | 136 | 72.00 | 99.90 | 52.83 | 83.26 |
| Total Debt | 403 | 126 | 202 | 217 | 49.83 | 49.86 | 49.77 | 31.11 | - | - |
| Net Cash / Debt | 19.18 | 229 | 267 | -11.14 | 59.01 | 86.26 | 22.23 | 68.79 | 52.83 | 83.26 |
| Assets | 566 | 440 | 520 | 262 | 182 | 166 | 102 | 135 | 65.76 | 91.35 |
| Liabilities | 474 | 191 | 312 | 294 | 139 | 125 | 122 | 85.87 | 54.86 | 70.99 |
| Book Value | 91.77 | 249 | 208 | -32.48 | 43.00 | 41.35 | -19.99 | 48.85 | 10.90 | 20.35 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Halozyme Therapeutics, Inc. |
| Country |
United States |
| Employees |
132 |
| CEO |
Helen I. Torley |
Stock Information
| Ticker Symbol |
HALO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: HALO |
Description
Halozyme Therapeutics operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.